Neonatal Metabolomic Signatures Predict Future IBD : Gastroenterology | May 2026

Introduction

Early-life environmental and immunologic exposures are increasingly implicated in the pathogenesis of Inflammatory bowel disease. Altered neonatal microbiota, elevated fecal calprotectin and immune dysregulation have previously been observed in children born to mothers with IBD, suggesting that disease susceptibility may begin very early in life. However, whether metabolic abnormalities are already detectable at birth in individuals who later develop Crohn’s disease or ulcerative colitis has remained unclear.

Problem Statement

Although metabolomic disturbances have been identified in established and preclinical IBD, studies investigating neonatal metabolic signatures preceding future disease onset are extremely limited. Determining whether altered metabolites are present immediately after birth could provide important mechanistic insight into early disease programming and identify novel biomarkers of future IBD susceptibility.

Summary

Using neonatal dried blood spots from the Danish National Biobank, this population-based cohort study performed untargeted metabolomics in 520 individuals who later developed IBD and 520 matched controls. Overall global metabolomic composition did not differ significantly between future IBD cases and controls. However, focused feature-selection analysis identified 21 metabolites associated with later Crohn’s disease and four metabolites associated with future ulcerative colitis. Notably, distinct metabolite signatures were observed for pediatric-onset and adult-onset disease, with no overlap between age-at-onset groups, suggesting divergent developmental trajectories of IBD susceptibility from birth onward.

The altered metabolites included amino acid derivatives, peptides, nucleotides/nucleosides and acyl-carnitines, implicating pathways related to protein turnover, mitochondrial metabolism and immune activation. Among the most biologically compelling findings was pseudouridine, which was strongly associated with future Crohn’s disease. Pseudouridine reflects increased transfer RNA turnover and has previously been linked to inflammatory signaling. The study demonstrated correlations between pseudouridine and inflammatory cytokines including TNF-α, IL-6 and IL-4, suggesting that neonatal immune activation may precede overt intestinal disease by many years. Genetic association analyses further linked several metabolites to loci involved in amino acid metabolism and mitochondrial transport pathways.

Importantly, no metabolites overlapped between Crohn’s disease and ulcerative colitis, reinforcing the concept that these conditions may have distinct early-life metabolic origins. The findings also differed from previous Canadian neonatal metabolomics studies, likely because of the broader untargeted metabolomic platform and use of dried blood spot specimens rather than serum. Although the study was exploratory and limited by incomplete metabolite annotation and lack of external validation, it provides important proof-of-concept evidence that metabolic perturbations associated with future IBD may already be present within days of birth. These results support the hypothesis that early developmental immune-metabolic programming contributes to later IBD susceptibility and establish a foundation for future mechanistic and predictive biomarker studies.